Adult Growth Hormone Deficiency

Endocrinology
7
Pipeline Programs
5
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
3
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
2 programs
1
Saizen® solution for injectionPhase 41 trial
Metabolic Endocrinology and Growth Hormone in AdultsN/A1 trial
Active Trials
NCT01080755CompletedEst. Sep 2012
NCT01806298CompletedEst. Mar 2016
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
3 programs
1
somapacitanPhase 31 trial
SomapacitanN/A1 trial
SomapacitanN/A1 trial
Active Trials
NCT05718570Enrolling By Invitation400Est. Dec 2032
NCT05230550Enrolling By Invitation200Est. Dec 2026
NCT02382939Completed92Est. Jan 2016
Ascendis Pharma
Ascendis PharmaCA - Palo Alto
2 programs
1
1
LonapegsomatropinPhase 31 trial
ACP-001Phase 21 trial
Active Trials
NCT01247675Completed37Est. May 2011
NCT05171855Completed220Est. Dec 2024
Opko Health
Opko HealthMIAMI, FL
2 programs
1
1
MOD-4023Phase 31 trial
MOD-4023Phase 21 trial
Active Trials
NCT01225666CompletedEst. Apr 2012
NCT01909479TerminatedEst. Aug 2018
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
Somatropin InjectionPhase 21 trial
Active Trials
NCT03104010UnknownEst. Sep 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Merck & Co.Saizen® solution for injection
Ascendis PharmaLonapegsomatropin
Novo Nordisksomapacitan
Opko HealthMOD-4023
Qilu PharmaceuticalSomatropin Injection
Ascendis PharmaACP-001
Opko HealthMOD-4023
Novo NordiskSomapacitan
Novo NordiskSomapacitan
Merck & Co.Metabolic Endocrinology and Growth Hormone in Adults

Clinical Trials (10)

Total enrollment: 949 patients across 10 trials

NCT01806298Merck & Co.Saizen® solution for injection

An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)

Start: Jun 2013Est. completion: Mar 2016
Phase 4Completed

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Start: Dec 2021Est. completion: Dec 2024220 patients
Phase 3Completed

A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

Start: Feb 2015Est. completion: Jan 201692 patients
Phase 3Completed

A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

Start: Jun 2013Est. completion: Aug 2018
Phase 3Terminated
NCT03104010Qilu PharmaceuticalSomatropin Injection

A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD

Start: Apr 2017Est. completion: Sep 2022
Phase 2Unknown

A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency

Start: Nov 2010Est. completion: May 201137 patients
Phase 2Completed

MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)

Start: Aug 2010Est. completion: Apr 2012
Phase 2Completed

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

Start: Feb 2023Est. completion: Dec 2032400 patients
N/AEnrolling By Invitation

Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

Start: Feb 2022Est. completion: Dec 2026200 patients
N/AEnrolling By Invitation
NCT01080755Merck & Co.Metabolic Endocrinology and Growth Hormone in Adults

Metabolic Endocrinology and Growth Hormone in Adults

Start: Dec 2003Est. completion: Sep 2012
N/ACompleted

Related Jobs in Endocrinology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space